Cargando…
Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
Guangdong province, located in South China, is an important economic hub with a large domestic migrant population and was among the earliest areas to report COVID-19 cases outside of Wuhan. We conducted a cross-sectional, age-stratified serosurvey to determine the seroprevalence of antibodies agains...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619097/ https://www.ncbi.nlm.nih.gov/pubmed/34832661 http://dx.doi.org/10.3390/pathogens10111505 |
_version_ | 1784604907494440960 |
---|---|
author | Xiao, Cheng Leung, Nancy Hiu Lan Cheng, Yating Lei, Hui Ling, Shiman Lin, Xia Tao, Ran Huang, Xianzhong Guan, Wenda Yang, Zifeng Cowling, Benjamin John Zanin, Mark Wong, Sook-San |
author_facet | Xiao, Cheng Leung, Nancy Hiu Lan Cheng, Yating Lei, Hui Ling, Shiman Lin, Xia Tao, Ran Huang, Xianzhong Guan, Wenda Yang, Zifeng Cowling, Benjamin John Zanin, Mark Wong, Sook-San |
author_sort | Xiao, Cheng |
collection | PubMed |
description | Guangdong province, located in South China, is an important economic hub with a large domestic migrant population and was among the earliest areas to report COVID-19 cases outside of Wuhan. We conducted a cross-sectional, age-stratified serosurvey to determine the seroprevalence of antibodies against SARS-CoV-2 after the emergence of COVID-19 in Guangdong. We tested 14,629 residual serum samples that were submitted for clinical testing from 21 prefectures between March and June 2020 for SARS-CoV-2 antibodies using a magnetic particle based chemiluminescent enzyme immunoassay and validated the results using a pseudovirus neutralization assay. We found 21 samples positive for SARS-CoV-2 IgG, resulting in an estimated age- and sex-weighted seroprevalence of 0.15% (95% CI: 0.06–0.24%). The overall age-specific seroprevalence was 0.07% (95% CI: 0.01–0.24%) in persons up to 9 years old, 0.22% (95% CI: 0.03–0.79%) in persons aged 10–19, 0.16% (95% CI: 0.07–0.33%) in persons aged 20–39, 0.13% (95% CI: 0.03–0.33%) in persons aged 40–59 and 0.18% (95% CI: 0.07–0.40%) in persons ≥60 years old. Fourteen (67%) samples had pseudovirus neutralization titers to S-protein, suggesting most of the IgG-positive samples were true-positives. Seroprevalence of antibodies to SARS-CoV-2 was low, indicating that there were no hidden epidemics during this period. Vaccination is urgently needed to increase population immunity to SARS-CoV-2. |
format | Online Article Text |
id | pubmed-8619097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86190972021-11-27 Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020 Xiao, Cheng Leung, Nancy Hiu Lan Cheng, Yating Lei, Hui Ling, Shiman Lin, Xia Tao, Ran Huang, Xianzhong Guan, Wenda Yang, Zifeng Cowling, Benjamin John Zanin, Mark Wong, Sook-San Pathogens Article Guangdong province, located in South China, is an important economic hub with a large domestic migrant population and was among the earliest areas to report COVID-19 cases outside of Wuhan. We conducted a cross-sectional, age-stratified serosurvey to determine the seroprevalence of antibodies against SARS-CoV-2 after the emergence of COVID-19 in Guangdong. We tested 14,629 residual serum samples that were submitted for clinical testing from 21 prefectures between March and June 2020 for SARS-CoV-2 antibodies using a magnetic particle based chemiluminescent enzyme immunoassay and validated the results using a pseudovirus neutralization assay. We found 21 samples positive for SARS-CoV-2 IgG, resulting in an estimated age- and sex-weighted seroprevalence of 0.15% (95% CI: 0.06–0.24%). The overall age-specific seroprevalence was 0.07% (95% CI: 0.01–0.24%) in persons up to 9 years old, 0.22% (95% CI: 0.03–0.79%) in persons aged 10–19, 0.16% (95% CI: 0.07–0.33%) in persons aged 20–39, 0.13% (95% CI: 0.03–0.33%) in persons aged 40–59 and 0.18% (95% CI: 0.07–0.40%) in persons ≥60 years old. Fourteen (67%) samples had pseudovirus neutralization titers to S-protein, suggesting most of the IgG-positive samples were true-positives. Seroprevalence of antibodies to SARS-CoV-2 was low, indicating that there were no hidden epidemics during this period. Vaccination is urgently needed to increase population immunity to SARS-CoV-2. MDPI 2021-11-18 /pmc/articles/PMC8619097/ /pubmed/34832661 http://dx.doi.org/10.3390/pathogens10111505 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Xiao, Cheng Leung, Nancy Hiu Lan Cheng, Yating Lei, Hui Ling, Shiman Lin, Xia Tao, Ran Huang, Xianzhong Guan, Wenda Yang, Zifeng Cowling, Benjamin John Zanin, Mark Wong, Sook-San Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020 |
title | Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020 |
title_full | Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020 |
title_fullStr | Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020 |
title_full_unstemmed | Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020 |
title_short | Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020 |
title_sort | seroprevalence of antibodies to sars-cov-2 in guangdong province, china between march to june 2020 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619097/ https://www.ncbi.nlm.nih.gov/pubmed/34832661 http://dx.doi.org/10.3390/pathogens10111505 |
work_keys_str_mv | AT xiaocheng seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT leungnancyhiulan seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT chengyating seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT leihui seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT lingshiman seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT linxia seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT taoran seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT huangxianzhong seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT guanwenda seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT yangzifeng seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT cowlingbenjaminjohn seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT zaninmark seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT wongsooksan seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 |